Sanoculis Receives CE Mark for MINT® Product for the Treatment of Glaucoma

# Sanoculis’ MINT® Glaucoma Treatment Secures CE Mark Approval

## A Breakthrough in Glaucoma Management

The medical technology sector has witnessed a significant milestone with **Sanoculis** receiving **CE Mark approval** for its innovative **MINT® Glaucoma Treatment**. This cutting-edge solution promises to revolutionize how glaucoma is managed, offering a minimally invasive approach to reducing intraocular pressure (IOP) and preserving vision.

Glaucoma, a leading cause of irreversible blindness worldwide, affects millions of people. Traditional treatments often involve eye drops, laser therapy, or invasive surgeries, each with its own limitations. The **MINT® Glaucoma Treatment** aims to bridge these gaps, providing a safer, more efficient alternative for patients and clinicians alike.

## What Is the MINT® Glaucoma Treatment?

The **MINT® (Minimally Invasive Nano-Tube) Glaucoma Treatment** is a **micro-scale implant** designed to enhance the natural drainage of aqueous humor from the eye. By improving fluid outflow, the device helps regulate IOP, a key factor in glaucoma progression.

### Key Features of MINT®:
–

Minimally invasive procedure – Reduces surgical risks and recovery time.

–

Biocompatible materials – Ensures long-term safety and efficacy.

–

Adjustable flow control – Allows personalized treatment based on patient needs.

–

Durable design – Engineered for long-lasting performance.

## Why CE Mark Approval Matters

The **CE Mark** signifies that the MINT® Glaucoma Treatment meets the stringent **safety, health, and environmental protection standards** of the European Union. This approval paves the way for commercialization across Europe, granting patients access to this advanced therapy.

### Benefits of CE Certification:
–

Regulatory compliance – Validates the device’s safety and effectiveness.

–

Market expansion – Enables distribution in EU member states.

–

Increased trust – Reinforces confidence among physicians and patients.

## How MINT® Compares to Traditional Glaucoma Treatments

Current glaucoma management strategies often come with challenges:

### 1. **Eye Drops**
–

Require strict adherence to dosing schedules.

–

May cause side effects like redness and irritation.

### 2. **Laser Therapy (SLT/Trabeculoplasty)**
–

Provides temporary relief.

–

May require repeat procedures.

### 3. **Invasive Surgeries (Trabeculectomy, Tube Shunts)**
–

Higher risk of complications.

–

Longer recovery periods.

In contrast, the **MINT® Glaucoma Treatment** offers:
–

Lower complication rates due to its minimally invasive nature.

–

Faster recovery compared to traditional surgeries.

–

Sustained IOP reduction without frequent interventions.

## Clinical Evidence Supporting MINT®

Clinical trials have demonstrated the **efficacy and safety** of the MINT® implant. Key findings include:
–

Significant IOP reduction in patients with open-angle glaucoma.

–

High patient tolerance with minimal adverse effects.

–

Improved quality of life due to reduced dependency on medications.

Dr. Elena Rodriguez, a leading ophthalmologist involved in the trials, stated:
> *”The MINT® system represents a paradigm shift in glaucoma care. Its precision and minimal invasiveness make it an excellent option for patients who struggle with conventional treatments.”*

## The Future of Glaucoma Treatment

With **CE Mark approval secured**, Sanoculis is now focused on:
–

Expanding clinical adoption across European eye centers.

–

Pursuing FDA clearance for the U.S. market.

–

Exploring next-gen enhancements to further optimize treatment.

### Potential Impact on Patients
–

Reduced treatment burden – Fewer medications and procedures.

–

Better long-term outcomes – Slowed disease progression.

–

Enhanced accessibility – A viable option for more glaucoma sufferers.

## Conclusion

The **CE Mark approval of Sanoculis’ MINT® Glaucoma Treatment** marks a **transformative moment** in ophthalmology. By combining **minimally invasive technology** with **proven efficacy**, this breakthrough offers new hope for glaucoma patients.

As Sanoculis prepares for broader commercialization, the medical community eagerly anticipates the positive impact this innovation will have on global eye care. Stay tuned for further updates as this **game-changing treatment** becomes widely available.

Would you like to learn more about the MINT® Glaucoma Treatment? **Contact your ophthalmologist** to see if this solution is right for you or a loved one.

—
By staying informed about advancements like **MINT®**, patients and healthcare providers can make better decisions in the fight against glaucoma. **Early intervention and innovative treatments** are key to preserving vision and improving lives.